186 related articles for article (PubMed ID: 26796981)
1. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
Sasaki K; Lahoti A; Jabbour E; Jain P; Pierce S; Borthakur G; Daver N; Kadia T; Pemmaraju N; Ferrajoli A; O'Brien S; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):152-62. PubMed ID: 26796981
[TBL] [Abstract][Full Text] [Related]
2. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Tong WG; Kantarjian H; O'Brien S; Faderl S; Ravandi F; Borthakur G; Shan J; Pierce S; Rios MB; Cortes J
Cancer; 2010 Jul; 116(13):3152-9. PubMed ID: 20564631
[TBL] [Abstract][Full Text] [Related]
3. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
4. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
Takahashi K; Kantarjian HM; Yang Y; Sasaki K; Jain P; DellaSala S; Ravandi F; Kadia T; Pemmaraju N; Daver N; Borthakur G; Garcia-Manero G; Jabbour E; Cortes JE
Cancer; 2016 Nov; 122(21):3336-3343. PubMed ID: 27509035
[TBL] [Abstract][Full Text] [Related]
5. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
6. Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Scalzulli E; Caocci G; Efficace F; Rizzo L; Colafigli G; Di Prima A; Pepe S; Fegatelli DA; Carmosino I; Diverio D; Latagliata R; La Nasa G; Martelli M; Foà R; Breccia M
Ann Hematol; 2021 May; 100(5):1213-1219. PubMed ID: 33677654
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.
Iriyama N; Sugimoto KJ; Sato E; Takaku T; Tokuhira M; Nakazato T; Ishikawa M; Fujita H; Fujioka I; Kimura Y; Asou N; Kizaki M; Komatsu N; Hatta Y; Kawaguchi T
Med Oncol; 2018 Sep; 35(11):142. PubMed ID: 30194496
[TBL] [Abstract][Full Text] [Related]
8. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Giles FJ; Abruzzese E; Rosti G; Kim DW; Bhatia R; Bosly A; Goldberg S; Kam GL; Jagasia M; Mendrek W; Fischer T; Facon T; Dünzinger U; Marin D; Mueller MC; Shou Y; Gallagher NJ; Larson RA; Mahon FX; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2010 Jul; 24(7):1299-301. PubMed ID: 20520639
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.
Cortes JE; Muresan B; Mamolo C; Cappelleri JC; Crescenzo RJ; Su Y; Gambacorti-Passerini C; Heeg B; Douglas Smith B
Curr Med Res Opin; 2019 Sep; 35(9):1615-1622. PubMed ID: 30964361
[No Abstract] [Full Text] [Related]
12. One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.
Signorovitch JE; Betts KA; Reichmann WM; Thomason D; Galebach P; Wu EQ; Chen L; DeAngelo DJ
Curr Med Res Opin; 2015 Feb; 31(2):315-22. PubMed ID: 25356603
[TBL] [Abstract][Full Text] [Related]
13. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Lipton JH
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
[TBL] [Abstract][Full Text] [Related]
14. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
15. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
[TBL] [Abstract][Full Text] [Related]
18. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.
Di Bella NJ; Bhowmik D; Bhor M; Yap M; Middlebrook B; Rembert D; Cain Z; Okoro T; Bolinder B; Patt D; Jabbour EJ
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):599-605. PubMed ID: 26208445
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Betts KA; Parikh K; Kantor E; Guo A; Bollu VK; Williams D; Wei LJ; DeAngelo DJ
Curr Med Res Opin; 2011 Jun; 27(6):1263-71. PubMed ID: 21524239
[TBL] [Abstract][Full Text] [Related]
20. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
